Debunking the notion that boosters don't reduce Omicron symptomatic infections. Another new study from Qatar shows they are halved medrxiv.org/content/10.110… matched >400,000 people with mRNA vaccines 2 vs 3-dose
Booster vaccine effectiveness vs Omicron infections 62% (2 dose 32%) @UKHSA in people without Prior Covid assets.publishing.service.gov.uk/government/upl…
and higher with Prior Covid, hybrid immunity, as seen in all studies
Since the booster protection vs Delta symptomatic infections was 95% and vs Omicron it is ~50%, that is a 10-fold increase in breakthroughs
Which is why there is the misperception that there is no booster protection from infections or transmission w/ Omicron
*when there is*
They are cut in half; 90% vs hospitalizations
I watched @billmaher and @bariweiss last night @RealTimers and it is so obvious they are not in touch with the data and, unfortunately, propagating misinformation
Adding this important study, the largest household (~12,000) contact study for Omicron and Delta infections and *impact of booster* (3rd) dose vaccination:
Infections were reduced OR 0.54, CI 0.40-0.71)
Transmission risk reduced OR: 0.72, CI: 0.56-0.92) medrxiv.org/content/10.110…
First post of this thread, Figure label correction by authors (Moderna, panel B, not Pfizer in both panels)
And full discussion of these findings erictopol.substack.com/p/where-do-we-…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…
3 New #LongCovid reports 1. Vaccination protection—1 dose 21%, 2 doses 59%, 3 doses 73% among ~590,000 people in Sweden (strong association) bmj.com/content/383/bm…
2. 3-year prospective follow up of a cohort of ~1350 participants, hospitalized in China
—Lung function restored back to baseline in most
—Higher risk of reinfection that people w/o Long Covid
—Half w/ persistent symptoms thelancet.com/journals/lanre…
3. At @RSNA annual meeting, brain MRI with microstructure imaging (DMI), participants with #LongCovid vs controls had microstructure changes associated with impaired cognition, sense of smell and fatigue eurekalert.org/news-releases/…
Big news #ESC2023 and @NEJM
In a placebo-controlled randomized trial of people with obesity + heart failure (with preserved ejection fraction). semaglutide (Wegovy) markedly improved symptoms, exercise time, reduced inflammatory markers (and weight loss) nejm.org/doi/full/10.10…
This also tells us something about the underlying mechanism of heart failure with preserved EF—metabolic dysfunction and attendant systemic inflammation—not previously acknowledged or confirmed
The accompanying editorial lays this finding out well. Prior studies of weight loss didn't help HFpEF